Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
2.8
-119.67%
40%
—
-96.58%
40%
—
5 Years
Score2.8
Net Growth-119.67%
Net Trend40%
Net Income Consistency—
Rev Growth-96.58%
Rev Trend40%
Revenue Consistency—
Ovid Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 12M to $ 7M and net income went from -$ 80M to -$ 17M. Revenue increased in 2 of those 5 years; net income in 2.
Ovid Therapeutics Inc currently holds a 5-year HDB Score of 2.8 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.62 | — |
1 Year2025-08-12 | $ 0.55 | 378.98% |
5 Years2021-08-12 | $ 3.91 | -32.99% |
All Time2017-05-05 | $ 12.25 | -78.61% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2017-05-05 |
|---|---|---|---|---|
| Price | $ 2.62 | $ 0.55 | $ 3.91 | $ 12.25 |
| Return | — | 378.98% | -32.99% | -78.61% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 7M | -$ 24M | $ 155M |
| 2025 | $ 7M | -$ 17M | $ 69M |
| 2024 | $ 566K | -$ 26M | $ 53M |
| 2023 | $ 392K | -$ 52M | $ 105M |
| 2022 | $ 1M | -$ 51M | $ 129M |
| 2021 | $ 208M | $ 122M | $ 187M |
| 2020 | $ 12M | -$ 80M | $ 72M |
| 2019 | $ 0.00 | -$ 59M | $ 76M |
| 2018 | $ 0.00 | -$ 51M | $ 41M |
| IPO2017 | $ 0.00 | -$ 64M | $ 87M |
Explore beyond OVID
You're looking at Ovid Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
